This topic contains 0 replies, has 1 voice, and was last updated by  MS News Today Moderator 1 month, 2 weeks ago.

  • Author
    Posts
  • #17500
     MS News Today Moderator 
    Participant

    Relapse events dropped by roughly half over a four-year period in relapsing-remitting multiple sclerosis (RRMS) patients treated with Aubagio (teriflunomide), a real-world study reports.

    The study also examined patients’ perspectives in terms of overall effectiveness, convenience, and satisfaction with the use of Aubagio. Learn more about the study and its findings here.

    Do you take or have you considered taking Aubagio?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account